EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Continuous Apomorphine Infusion in Multiple System Atrophy Real‐World Insights From a French Nationwide Retrospective Cohort

Simon Lamy iD, Frederique Leh, Alexandra Foubert-Samier, Soizic Leguy Bonnet, Guillaume Baille iD, Margherita Fabbri, Margaux Dunoyer, Lise Mantisi, Caroline Giordana, Anaïs El Ouartassi, Olivier Rascol, Wassilios G Meissner iD und 5 weitere

Movement Disorders Clinical Practice · 19.04.2026

DOI: 10.1002/mdc3.70644 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 19.04.2026. Verfasst von Simon Lamy und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Pontchaillou University Hospital, Rennes, France. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Continuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA).

Objective

To assess the 6‐month efficacy and tolerability of CSAI in MSA patients.

Methods

French multicenter retrospective registry‐based analysis of CSAI use in MSA. The primary outcome was the 6‐month clinical response using the Clinical Global Impression Improvement (CGI‐I) scale. Secondary outcomes included tolerability, indications, infusion parameters, and treatment course.

Results

Fifty patients were included; 94% had MSA‐P. All had motor fluctuations and 88% showed a clinically meaningful dopaminergic response. CSAI was initiated for motor symptoms (100%) or pain (54%). At 6 months, most patients improved (36% “much,” 54% “minimally”), mainly due to reduced motor fluctuations. Only 8% discontinued CSAI. Tolerability was rated good/excellent in 74%; 20% reported somnolence and/or orthostatic hypotension.

Conclusion

In selected MSA patients with partial dopaminergic responsiveness and motor fluctuations, CSAI provided short‐term clinical benefit with acceptable tolerability.

Schlagwörter

Stichwörter der Autor:innen

MSAapomorphinefluctuationsinfusionparkinsonism

Autor:innen und Institutionen

  • Department of Neurology, Pontchaillou University Hospital, Rennes, France.
  • Department of Neurology, Pontchaillou University Hospital, CIC INSERM 1414 Rennes, Rennes, France.
  • CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, IMNc, CRMR AMS, Bordeaux, France.
  • Université de Bordeaux, CNRS, IMN, UMR5293, Bordeaux, France.
  • Bordeaux Population Health Research Center, Inserm U1219, University of Bordeaux, Bordeaux, France.
  • Cabinet de Neurologie Libérale, Saint-Malo, France.

ORCID-Profile: Simon Lamy, Guillaume Baille, Wassilios G Meissner

Zitieren

APA

Lamy, S., Leh, F., Foubert-Samier, A., Leguy Bonnet, S., Baille, G., Fabbri, M., Dunoyer, M., Mantisi, L., Giordana, C., El Ouartassi, A., Rascol, O., Meissner, W. G., Bendetowicz, D., Vanel, M., Grabli, D., Ory-Magne, F., & Drapier, S. (2026). Continuous Apomorphine Infusion in Multiple System Atrophy Real‐World Insights From a French Nationwide Retrospective Cohort. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70644

Vancouver

Lamy S, Leh F, Foubert-Samier A, Leguy Bonnet S, Baille G, Fabbri M, et al. Continuous Apomorphine Infusion in Multiple System Atrophy Real‐World Insights From a French Nationwide Retrospective Cohort. Movement Disorders Clinical Practice. 2026. doi:10.1002/mdc3.70644

BibTeX
@article{Lamy2026,
  author = {Lamy, Simon and Leh, Frederique and Foubert-Samier, Alexandra and Leguy Bonnet, Soizic and Baille, Guillaume and Fabbri, Margherita and Dunoyer, Margaux and Mantisi, Lise and Giordana, Caroline and El Ouartassi, Anaïs and Rascol, Olivier and Meissner, Wassilios G and Bendetowicz, David and Vanel, Marie and Grabli, David and Ory-Magne, Fabienne and Drapier, Sophie},
  title = {Continuous Apomorphine Infusion in Multiple System Atrophy Real‐World Insights From a French Nationwide Retrospective Cohort},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  doi = {10.1002/mdc3.70644}
}
Kostenlos starten →